Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Immune checkpoint blockade has shown significant promise as an anticancer treatment, yet the determinants of response are not completely understood. Here we show that somatic mutations in SERPINB3 and SERPINB4 are associated with survival after anti-CTLA4 immunotherapy in two independent cohorts of patients with melanoma (n = 174). Interestingly, serpins are homologs of the well-known ovalbumin antigen and are associated with autoimmunity. Our findings have implications for the personalization of immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationNivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Genomic classification of cutaneous melanoma
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.044 · Cited by 3,151
Self-citationClonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Self-citationGenomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Recent advances in the understanding of egg allergens: basic, industrial, and clinical perspectives
Mine, Y., & Yang, M. (2008) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf8001153 · Cited by 196
Research works printed but not linked: 27
- Hodi, F.S. et al. N. Engl. J. Med. 363, 711–723 (2010). · DOI · Paper page
- Snyder, A. et al. N. Engl. J. Med. 371, 2189–2199 (2014). · DOI · Paper page
- Vidalino, L. et al. Autoimmun. Rev. 9, 108–112 (2009). · doi:10.1016/j.autrev.2009.03.011
- Gatto, M. et al. Clin. Rev. Allergy Immunol. 45, 267–280 (2013). · DOI
- Sivaprasad, U. et al. J. Invest. Dermatol. 135, 160–169 (2015). · DOI
- Schneider, S.S. et al. Proc. Natl. Acad. Sci. USA 92, 3147–3151 (1995). · DOI · Paper page
- Catanzaro, J.M. et al. Nat. Commun. 5, 3729 (2014). · DOI
- Guan, J., Gupta, R. & Filipp, F.V. Sci. Rep. 5, 7857 (2015). · DOI · Paper page
- Katagiri, C., Nakanishi, J., Kadoya, K. & Hibino, T. J. Cell Biol. 172, 983–990 (2006). · DOI
- El-Rachkidy, R.G., Young, H.S., Griffiths, C.E. & Camp, R.D. J. Invest. Dermatol. 128, 2219–2224 (2008). · DOI
- Lysvand, H., Hagen, L., Klubicka, L., Slupphaug, G. & Iversen, O.J. Biochim. Biophys. Acta 1842, 734–738 (2014). · doi:10.1016/j.bbadis.2014.02.005
- Münz, C. Front. Immunol. 3, 9 (2012). · DOI
- Schumacher, T. et al. Nature 512, 324–327 (2014). · DOI · Paper page
- Holen, E. & Elsayed, S. Clin. Exp. Allergy 26, 1080–1088 (1996). · DOI
- DePristo, M.A. et al. Nat. Genet. 43, 491–498 (2011). · DOI · Paper page
- Li, H. & Durbin, R. Bioinformatics 25, 1754–1760 (2009). · DOI · Paper page
- McKenna, A. et al. Genome Res. 20, 1297–1303 (2010). · DOI · Paper page
- Cibulskis, K. et al. Nat. Biotechnol. 31, 213–219 (2013). · DOI · Paper page
- Koboldt, D.C. et al. Genome Res. 22, 568–576 (2012). · DOI · Paper page
- Larson, D.E. et al. Bioinformatics 28, 311–317 (2012). · DOI · Paper page
- Saunders, C.T. et al. Bioinformatics 28, 1811–1817 (2012). · DOI · Paper page
- Strona, G., Nappo, D., Boccacci, F., Fattorini, S. & San-Miguel-Ayanz, J. Nat. Commun. 5, 4114 (2014). · DOI · Paper page
- Kim, J. et al. Nat. Genet. 48, 600–606 (2016). · DOI · Paper page
- Schellens, I.M. et al. PLoS One 10, e0136417 (2015). · DOI
- Snyder, A. & Chan, T.A. Curr. Opin. Genet. Dev. 30, 7–16 (2015). · DOI · Paper page
- Nielsen, M. et al. Protein Sci. 12, 1007–1017 (2003). · DOI · Paper page
- Andreatta, M. et al. Immunogenetics 67, 641–650 (2015). · DOI · Paper page
Cited by
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Chan, T. A., Yarchoan, M., Jaffee, E., Swanton, C., Quezada, S. A., Stenzinger, A., & Peters, S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy495 · Cited by 2,683
Self-citationTumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Urba, W. J., Sims, J. S., Hodi, F. S., Martín-Algarra, S., Mandal, R., Sharfman, W. H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.028 · Cited by 2,401
“High tumor mutation load may increase the probability of generating immunogenic neoantigens, which facilitate recognition of a tumor as foreign (Riaz et al., 2016a; Schumacher and Schreiber, 2015).”
BackgroundSelf-citationThe evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Self-citationThe Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker
Jardim, D. L., Goodman, A., de Melo Gagliato, D., & Kurzrock, R. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.10.001 · Cited by 1,192
Metadata
- Authors
- Riaz, N., Havel, J. J., Kendall, S. M., Makarov, V., Walsh, L. A., Desrichard, A., Weinhold, N., & Chan, T. A.
- Venue
- Nature Genetics
- Published
- 2016-09-26
- Volume
- 48
- Issue
- 11
- Pages
- 1327-1329
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2524088453
- Cited by
- 150
- References
- 10
- FWCI
- 7.11
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy. https://app.cochat.ai/papers/10.1038/ng.3677
- The paper
- Riaz, N., Havel, J. J., Kendall, S. M., Makarov, V., Walsh, L. A., Desrichard, A., Weinhold, N., & Chan, T. A. (2016). Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy. Nature Genetics. https://doi.org/10.1038/ng.3677
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.